ArticleClinical rheumatology2022
Interleukin-35 promotes Breg expansion and interleukin-10 production in CD19
Article in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- The Framework of Host Innate and Adaptive Immunological Pathways.Biomedicines · 2026Review
- Regulatory B cells, the key regulator to induce immune tolerance in organ transplantation.Frontiers in immunology · 2025Review
- The immune tolerance role of Bregs in inhibiting human inflammatory diseases, with a focus on diabetes mellitus.Frontiers in immunology · 2025Review
- Ex vivo-generated human CD1cMolecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Butyrate: a bridge between intestinal flora and rheumatoid arthritis.Frontiers in immunology · 2024Review
- B lymphocytes transdifferentiate into immunosuppressive erythroblast-like cells.Frontiers in immunology · 2023Article
- The yin and yang of B cells in a constant state of battle: intestinal inflammation and inflammatory bowel disease.Frontiers in immunology · 2023Review
- The HMGB1 (C106A) mutation inhibits IL-10-producing CD19Frontiers in immunology · 2022Article
- Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.Frontiers in immunology · 2022Review
- Unraveling the role of Breg cells in digestive tract cancer and infectious immunity.Frontiers in immunology · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveIL-35 is a potent immunosuppressive and anti-inflammatory cytokine, consisting of a p35 subunit and an Epstein-Barr virus-induced gene 3 (EBI3) subunit, which suppresses CD4
methodsA total of 77 patients with AS (AS group), including 47 inactive AS and 30 active AS cases, and 59 healthy controls (HCs) were enrolled into this study. The serum levels of IL-35 and IL-10 were detected by ELISA, and the mRNA levels of p35 and EBI3 were measured by RT-qPCR. The percentages of CD19
resultsThe serum IL-35 and IL-10 levels, p35 and EBI3 mRNA levels, and the percentages of CD19
conclusionThese results demonstrated that reduced IL-35 production may be associated with Bregs defects in AS patients. RIL-35 induced the proliferation of CD19
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.